So, in our opinion, more retrospective studies in larger series of primary tumors are still necessary, to understand the role of NIS expression in therapy response, tumor behavior and prognosis, and also if other factors besides BRAFV600E mutation can contribute to NIS downregulation and/or misdirecting to the basolateral membrane. This evidence concerns the gene SLC5A5 and neoplasm.